H101
Sponsors
Sun Yat-sen University, Southwest Hospital, China, Liu Zi, Fudan University, Jun Huang
Conditions
Advanced Biliary Tract CancerBiliary Tract Cancer (BTC)CRCGenital Neoplasms, FemaleHead and Neck Squamous Cell CarcinomaHepatocellular CarcinomaLiver Metastasis Colon CancerOncolytic Virus
Phase 1
Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites
NCT05303844
Start: 2022-04-02End: 2025-03-20Target: 25Updated: 2023-04-12
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer
CompletedNCT05303090
Start: 2022-03-31End: 2024-04-23Updated: 2025-02-27
Phase 2
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
Active, not recruitingNCT05051696
Start: 2021-09-26End: 2025-03-30Updated: 2024-06-04
Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)
NCT05823987
Start: 2023-05-16End: 2025-12-30Target: 25Updated: 2023-06-27
Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
Not yet recruitingNCT06196671
Start: 2026-12-01End: 2028-01-01Target: 30Updated: 2025-08-07
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
Not yet recruitingNCT06919848
Start: 2025-05-01End: 2027-05-01Target: 74Updated: 2025-04-09
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM
Not yet recruitingNCT07381309
Start: 2026-06-01End: 2029-02-01Target: 114Updated: 2026-04-28
H101 Plus TACE for r/m HNSCC
RecruitingNCT07398664
Start: 2026-03-02End: 2028-12-15Target: 20Updated: 2026-07-17